Scientists in the US have developed a drug used in cancer treatment to awaken the so-called sleeper cells in patients receiving treatment for HIV, the virus that causes AIDS. Researchers said they had found a way to stimulate the emergence of the virus using an anti-cancer drug, noting that this may be the first step towards the development of a potential cure for the virus that causes AIDS. Under the supervision of David Margolis of The University of North Carolina at Chapel Hill, researchers were able to cooperate with their colleagues from other universities and researchers at global pharmaceutical and chemical company Merck, proving that this molecular mechanism works using a specific drug. Known in the US as a medicine against cancer, it is traded under the brand name Zolinza. "We believe that the disruption and clearance of these virus reservoirs is a critical first step to the daunting challenge of finding a cure for HIV/AIDS," said Merck Research Laboratories Vice President Daria Hazuda. This is the first published study to show the potential for inhibitors to attack latency within dormant virus pools in a translational clinical study.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor